Selumetinib sulfate

{
  "id": "MLC-T-ONC-007649",
  "term": "Selumetinib sulfate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat children aged 2 years and older with a rare genetic condition called neurofibromatosis type 1. It is used in patients who have plexiform neurofibromas that are causing symptoms and cannot be removed by surgery. It is also being studied in the treatment of some types of cancer. Selumetinib sulfate blocks proteins called MEK1 and MEK2, which may help keep abnormal cells or cancer cells from growing. It is a type of kinase inhibitor. Also called AZD6244, Koselugo, and MEK inhibitor AZD6244.",
    "The sulfate salt of selumetinib, an orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
  ],
  "synonyms": [
    "AZD6244",
    "Koselugo",
    "MEK inhibitor AZD6244",
    "selumetinib sulphate"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/selumetinib-sulfate/"
}